EcoDrugPlus

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSAOCG00000018871
Gene Symbol: LOC111581460
2 Cross references
193 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSAOCG00000016321
Gene Symbol: LOC111568093
3 Cross references
168 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSAOCG00000020260
Gene Symbol: LOC111577378
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSAOCG00000002390
Gene Symbol: LOC111568113
3 Cross references
181 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSAOCG00000016359
Gene Symbol: LOC111568110
3 Cross references
188 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSAOCG00000014309
Gene Symbol: LOC111564003
3 Cross references
229 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-2-Like

Ensembl ID : ENSAOCG00000010683
Gene Symbol: LOC111579902
3 Cross references
213 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSAOCG00000020158
Gene Symbol: XDH
3 Cross references
211 Possible Orthologues:

Ensembl ID : ENSAOCG00000016283
Gene Symbol: -
Cross references: -
241 Possible Orthologues:

Ensembl ID : ENSAOCG00000020418
Gene Symbol: -
Cross references: -
194 Possible Orthologues:

Ensembl ID : ENSAOCG00000016258
Gene Symbol: -
Cross references: -
214 Possible Orthologues:

Ensembl ID : ENSAOCG00000024250
Gene Symbol: -
Cross references: -
247 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).